Companies / Curis, Inc. / Activity
Activity — Curis, Inc.
31 moves.
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Kaitin Kenneth I Director | Buy | Common Stock | $5.5K | +10K +710.73% | 11,407 0.03% of shares | low |
| Mar 20, 2026 | Zung Jonathan B. Executive | Other | Series B Convertible Preferred Stock | — | -50 -100.00% | 0 0.00% of shares | low |
| Mar 20, 2026 | Zung Jonathan B. Executive | Other | Common Stock | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Zung Jonathan B. Executive | Grant | Series C Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Zung Jonathan B. Executive | Grant | Series B Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Zung Jonathan B. Executive | Grant | Series A Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Zung Jonathan B. Executive | Grant | Series B Convertible Preferred Stock | — | +50 | 50 <0.01% of shares | low |
| Mar 20, 2026 | Duvall Diantha Executive | Other | Series B Convertible Preferred Stock | — | -50 -100.00% | 0 0.00% of shares | low |
| Mar 20, 2026 | Duvall Diantha Executive | Other | Common Stock | — | +67K +603.80% | 77,707 0.20% of shares | low |
| Mar 17, 2026 | Duvall Diantha Executive | Grant | Series C Warrant (right to buy) | — | +67K | 66,666 0.17% of shares | low |
| Mar 17, 2026 | Duvall Diantha Executive | Grant | Series B Warrant (right to buy) | — | +67K | 66,666 0.17% of shares | low |
| Mar 17, 2026 | Duvall Diantha Executive | Grant | Series A Warrant (right to buy) | — | +67K | 66,666 0.17% of shares | low |
| Mar 17, 2026 | Duvall Diantha Executive | Grant | Series B Convertible Preferred Stock | — | +50 | 50 <0.01% of shares | low |
| Mar 20, 2026 | Hamdy Ahmed MD Executive | Other | Series B Convertible Preferred Stock | — | -50 -100.00% | 0 0.00% of shares | low |
| Mar 20, 2026 | Hamdy Ahmed MD Executive | Other | Common Stock | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Hamdy Ahmed MD Executive | Grant | Series C Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Hamdy Ahmed MD Executive | Grant | Series B Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Hamdy Ahmed MD Executive | Grant | Series A Warrant (right to buy) | — | +67K | 66,667 0.17% of shares | low |
| Mar 17, 2026 | Hamdy Ahmed MD Executive | Grant | Series B Convertible Preferred Stock | — | +50 | 50 <0.01% of shares | low |
| Mar 20, 2026 | Rubin Marc Director | Other | Series B Convertible Preferred Stock | — | -20 -100.00% | 0 0.00% of shares | low |
| Mar 20, 2026 | Rubin Marc Director | Other | Common Stock | — | +27K +1850.59% | 28,108 0.07% of shares | low |
| Mar 17, 2026 | Rubin Marc Director | Grant | Series C Warrant (right to buy) | — | +27K | 26,667 0.07% of shares | low |
| Mar 17, 2026 | Rubin Marc Director | Grant | Series B Warrant (right to buy) | — | +27K | 26,667 0.07% of shares | low |
| Mar 17, 2026 | Rubin Marc Director | Grant | Series A Warrant (right to buy) | — | +27K | 26,667 0.07% of shares | low |
| Mar 17, 2026 | Rubin Marc Director | Grant | Series B Convertible Preferred Stock | — | +20 | 20 <0.01% of shares | low |
| Mar 20, 2026 | Dentzer James E CEO | Other | Series B Convertible Preferred Stock | — | -100 -100.00% | 0 0.00% of shares | low |
| Mar 20, 2026 | Dentzer James E CEO | Other | Common Stock | — | +133K +865.97% | 148,730 0.38% of shares | low |
| Mar 17, 2026 | Dentzer James E CEO | Grant | Series C Warrant (right to buy) | — | +133K | 133,333 0.34% of shares | low |
| Mar 17, 2026 | Dentzer James E CEO | Grant | Series B Warrant (right to buy) | — | +133K | 133,333 0.34% of shares | low |
| Mar 17, 2026 | Dentzer James E CEO | Grant | Series A Warrant (right to buy) | — | +133K | 133,333 0.34% of shares | low |
| Mar 17, 2026 | Dentzer James E CEO | Grant | Series B Convertible Preferred Stock | — | +100 | 100 <0.01% of shares | low |